This article is more than 5 years old. Information may no longer be current.
Regentis Biomaterials receives CE mark for implant for traumatic knee injury
Regentis Biomaterials Ltd. received European CE mark approval for its GelrinC biodegradable implant suitable for patients with traumatic knee injuries.
A synthetic implant, GelrinC provides a customized solution by completely filling cartilage lesions with acellular material, according to a company press release. It allows high-quality cartilage to regenerate in the knee in the exact shape of the defect and is inserted as a liquid to fill any shape of cartilage defect. The material is then converted into a solid through exposure to ultraviolet light.
“This approval represents a major milestone in the development of cartilage repair technologies since it enhances growth of high-quality cartilage that fits tightly with the surrounding cartilage and underlying bone,” Alastair Clemow, PhD, president and chief executive officer of Regentis Biomaterials, stated in a press release. “With CE mark approval, we look forward to making GelrinC available to European patients to help them return to an active lifestyle.”